Paul R Massey
Overview
Explore the profile of Paul R Massey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dodson J, Ibrahim S, Rogers H, Council M, Nehal K, Tung R, et al.
J Am Acad Dermatol
. 2023 Dec;
90(4):798-805.
PMID: 38081390
Background: Amid a movement toward value-based healthcare, increasing emphasis has been placed on outcomes and cost of medical services. To define and demonstrate the quality of services provided by Mohs...
2.
Extensive Perineural Invasion vs Nerve Caliber to Assess Cutaneous Squamous Cell Carcinoma Prognosis
Massey P, Wang D, Murad F, Mulvaney P, Moore K, Okhovat J, et al.
JAMA Dermatol
. 2023 Oct;
159(12):1332-1338.
PMID: 37851425
Importance: Perineural invasion (PNI) is an adverse risk feature in cutaneous squamous cell carcinoma (CSCC) that affects patient prognosis and disease management. However, research comparing different PNI patterns on patient...
3.
Bottomley M, Massey P, Thuraisingham R, Doyle A, Rao S, Bibee K, et al.
Transpl Int
. 2022 Dec;
35:10880.
PMID: 36484063
Cutaneous squamous cell carcinoma (CSCC) is a major cause of morbidity and mortality after organ transplant. Many patients subsequently develop multiple CSCC following a first CSCC, and the risk of...
4.
Massey P, Schmults C, Li S, Arron S, Asgari M, Bouwes Bavinck J, et al.
JAMA Dermatol
. 2021 Sep;
157(10):1219-1226.
PMID: 34468690
Importance: There is a paucity of evidence to guide physicians regarding prevention strategies for cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients (SOTRs). Objective: To examine the development...
5.
Massey P, Rothstein B, Gupta S, Sigel K, Schmults C, Waldman A
Dermatol Surg
. 2021 Jul;
47(9):1220-1223.
PMID: 34238788
Background: Practice variation has been well documented across the US health care system but has not been explored in reconstructive surgical choice after keratinocyte carcinoma (KC) extirpation. Objective: Assess practice...
6.
Becker N, Bakshi S, Martin K, Bougrine A, Andrade J, Massey P, et al.
Acad Med
. 2021 Jun;
96(12):1717-1721.
PMID: 34133344
Problem: The SARS-CoV-2 (COVID-19) pandemic presented numerous challenges to inpatient care, including overtaxed inpatient medicine services, surges in patient censuses, disrupted patient care and educational activities for trainees, underused providers...
7.
Mulvaney P, Massey P, Yu K, Drinan J, Schmults C
J Invest Dermatol
. 2021 Mar;
141(9):2161-2169.
PMID: 33771528
The majority of cutaneous squamous cell carcinomas are treated by surgical removal; however, approximately 4% of tumors will metastasize. Molecular expression testing may improve accuracy in estimating the prognosis and...
8.
Massey P, Gupta S, Rothstein B, Konnikov N, Mahalingam M, Ruiz E, et al.
Ann Surg Oncol
. 2021 Mar;
28(7):3656-3663.
PMID: 33742233
Background: Keratinocyte carcinoma (KC), including basal and squamous cell carcinoma, is the most common human malignancy. Limited real-world data have compared surgical outcome or cost between total margin-controlled excision (TMCE)...
9.
McAndrew R, Massey P, Diaz L, Levy M
Pediatr Rev
. 2020 Sep;
41(9):e34-e36.
PMID: 32873568
No abstract available.
10.
Massey P, Jones K
Semin Oncol
. 2020 Aug;
47(5):330-334.
PMID: 32736881
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the COVID-19 global pandemic, is notable for an expanding list of atypical manifestations including but not limited to coagulopathies, renal...